Properties of multidrug-resistant, ESBL-producing Proteus mirabilis isolates and possible role of β-lactam/β-lactamase inhibitor combinations

International Journal of Antimicrobial Agents

Volumn 17, Issue 2, 2001, Pages 131-135

  Luzzaro, Francesco ^a   Perilli, Mariagrazia ^b   Amicosante, Gianfranco ^b   Lombardi, Gianluigi ^a   Belloni, Renzo ^a   Zollo, Alessanro ^c   Bianchi, Ciro ^c   Toniolo, Antonio ^a  

^a UNIVERSITY OF INSUBRIA   (Italy)

^b UNIVERSITY OF L'AQUILA   (Italy)

^c Wyeth Lederle Vaccines   (Italy)

Author keywords

Extended spectrum lactamase; Multidrug resistance; Proteus mirabilis; lactam lactamase inhibitor combination

Indexed keywords

AMIKACIN; AZTREONAM; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; BETA LACTAMASE INHIBITOR; CEFOTAXIME; CEFOXITIN; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLAVULANIC ACID; COTRIMOXAZOLE; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TAZOBACTAM;

ANTIBIOTIC RESISTANCE; ARTICLE; CONTROLLED STUDY; DRUG POTENTIATION; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROTEUS MIRABILIS;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; CEPHALOSPORINS; CLAVULANIC ACID; DRUG RESISTANCE, MICROBIAL; DRUG RESISTANCE, MULTIPLE; ENZYME INHIBITORS; GENES, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; PENICILLANIC ACID; PROTEUS INFECTIONS; PROTEUS MIRABILIS;

EID: 0035145466     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(00)00325-3     Document Type: Article

References (26)

1. Clinical relevance of Proteus mirabilis in hospital patients: a 2-year survey
2. β-Lactam resistance in gram-negative bacteria: global trends and clinical impact
3. Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens
4. Escherichia coli and Klebsiella pneumoniae more susceptible to cefoxitin than to third-generation cephalosporins
5. Evaluation of clonal relatedness of extended-spectrum β-lactamase-producing Proteus mirabilis isolates by quantitative antibiogram and RAPD typing
6. Resistance to cefotaxime and seven others β-lactams in members of the family Enterobacteriaceae: a 3-year survey in France
7. Antimicrobial resistance in Enterobacteriaceae in Brooklyn, NY: epidemiology and relation to antibiotic usage patterns
8. Resistance profile of Enterobacteriaceae showing synergy between clavulanate and β-lactams: an Italian survey
9. Tazobactam-piperacillin compared with sulbactam-ampicillin, clavulanic acid-ticarcillin, sulbactam-cefoperazone, and piperacillin for activity against beta-lactamase-producing bacteria isolated from patients with complicated urinary tract infections
10. Comparative antimicrobial activity of piperacillin-tazobactam tested against more than 5000 recent clinical isolates from five medical centers. A re-evaluation after five years
11. National survey of the in vitro spectrum of piperacillin-tazobactam tested against more than 40 000 aerobic clinical isolates from 236 medical centers
12. Piperacillin/tazobactam: a critical review of the evolving clinical literature
13. Extended broad-spectrum β-lactamases conferring transferable resistance to newer β-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns
14. Direct sequencing of the amplified structural gene and promoter for the extended-broad-spectrum β-lactamase TEM-9 (RHH-1) of Klebsiella pneumoniae
15. β-Lactamase in laboratory and clinical resistance
16. New variant of TEM-10 β-lactamase gene produced by a clinical isolate of Proteus mirabilis
17. TEM-24 produced by four different species of Enterobacteriaceae, including Providencia rettgeri, in a single patient
18. β-Lactamases responsible for resistance to expanded-spectrum cephalosporins in Klebsiella pneumoniae, Escherichia coli, and Proteus mirabilis isolates recovered in South Africa
19. Extended-spectrum β-lactamase in Proteus mirabilis
20. Diversity of TEM mutants in Proteus mirabilis
21. A novel extended-spectrum TEM-type β-lactamase (TEM-52) associated with decreased susceptibility to moxalactam in Klebsiella pneumoniae
22. Permeability to carbapenems of Proteus mirabilis mutants selected for resistance to imipenem or other β-lactams
23. Characterization of an inhibitor-resistant enzyme IRT-2 derived from TEM-2 β-lactamase produced by Proteus mirabilis strains
24. Inhibitor-resistant TEM β-lactamases: phenotypic, genetic and biochemical characteristics